Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
15 nov. 2024 13h15 HE
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14 nov. 2024 08h10 HE
|
ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
28 oct. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct....
The American Kidney Fund Launches ‘Answers Unlocked’ Educational Campaign to Help Kidney Patients Learn About the Benefits of Genetic Testing
22 oct. 2024 12h17 HE
|
American Kidney Fund
ROCKVILLE, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched its newest educational campaign, “Answers Unlocked,” to spread awareness of the need and benefits of...
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
16 oct. 2024 16h35 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
On the Heels of Historic Hurricane Helene, American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Hurricane Milton
10 oct. 2024 13h07 HE
|
American Kidney Fund
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has turned on its Disaster Relief Program to aid dialysis and post-transplant patients living in areas impacted by...
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
09 oct. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 02h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
08 oct. 2024 09h00 HE
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...